Tanfanercept

DB19142InvestigationalProtein Based Therapies

Tanfanercept is under investigation in clinical trial NCT06400589 (A Study to Evaluate the Efficacy and Safety of Tanfanercept (HL036) in Dry Eye Disease).

Mechanism: Pharmacologically active on Tumor necrosis factor
Curator reviewed
Also known as: 41-211-tumor necrosis factor receptor 1 · L-methionyl-(l28>v,s52>m,h55>f,r57>p,h58>g,k121>n) tumor necrosis factor (tnf) binding protein variant 1 (tbp-1) with c-terminal extension by further 10 residues of the pro-protein, human, unglycosylated
Code names: HBM9036 · HL036 · HL-036337

Resolves to

Compound

UNIIZ39Q6AB0ZRCAS2119738-70-2

Targets

P01375TNF

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

7Clinical trialsPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with Tanfanercept, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account